Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71200 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Giacomo Ruotolo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly & Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Recombinant Fusion Proteins, Glucagon-Like Peptides. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). Materials and Methods Data were analysed from two randomised, double‐blind, placebo‐controlled phase 2 trials. In Study 1, adults with obesity/overweight and T2D received once‐weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks. Fasting blood samples were collected at baseline and during treatment to assess lipids, apolipoproteins, lipoprotein particle subclasses and inflammatory biomarkers. Mixed models for repeated measures estimated placebo‐adjusted change from baseline. Statistical significance was defined as a false discovery rate‐adjusted p < 0.05.
Results
Mean body mass index was 35.4 kg/m 2 (Study 1) and 37.4 kg/m 2 (Study 2). In both studies, retatrutide was associated with significant reductions in non‐high‐density lipoprotein cholesterol (Study 1: up to −21.0%, Study 2: up to −26.9%), apolipoprotein B (−21.4%, −24.2%), total triglyceride‐rich lipoprotein particles (−22.5%, −33.7%), large triglyceride‐rich lipoprotein particles (−84.4%, −76.6%), triglyceride‐rich lipoprotein cholesterol (−29.4%, −38.6%), total low‐density lipoprotein particles (−19.7%, −23.5%) and small low‐density lipoprotein particles (−32.6%, −32.3%). Retatrutide was associated with significant reductions in high‐sensitivity C‐reactive protein (−54.8%) and interleukin‐6 (−29.6%) in Study 2 but not Study 1.
Conclusions
In adults with obesity/overweight, with or without T2D, retatrutide treatment was associated with reductions in atherogenic lipoproteins and inflammatory biomarkers linked to cardiovascular disease risk. Trial Registration: ClinicalTrials.gov numbers NCT04881760 and NCT04867785
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eli Lilly & Company, Indianapolis, Indiana, USA.
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
- Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia.
ORCID-Profile: Giacomo Ruotolo, Melissa K Thomas, Tamer Coskun, Axel Haupt, Naveed Sattar
Förderung
- Eli Lilly and Company
Zitieren
APA
Ruotolo, G., Harris, C., Lin, Y., Wilson, J. M., Pirro, V., Duffin, K. L., Thomas, M. K., Hartman, M. L., Neill, C. O., Coskun, T., Milicevic, Z., Haupt, A., Sattar, N., & Nicholls, S. J. (2026). Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71200
Vancouver
Ruotolo G, Harris C, Lin Y, Wilson JM, Pirro V, Duffin KL, et al. Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71200
BibTeX
@article{Ruotolo2026,
author = {Ruotolo, Giacomo and Harris, Charles and Lin, Yanzhu and Wilson, Jonathan M and Pirro, Valentina and Duffin, Kevin L and Thomas, Melissa K and Hartman, Mark L and Neill, Ciara O' and Coskun, Tamer and Milicevic, Zvonko and Haupt, Axel and Sattar, Naveed and Nicholls, Stephen J},
title = {Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71200}
}
EUVIMED